Wikisage, the free encyclopedia of the second generation, is digital heritage
Lamictal XR: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
mNo edit summary |
||
| Line 1: | Line 1: | ||
lamotrigine slow release<ref>https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lamictal_XR/pdf/LAMICTAL-XR-PI-MG.PDF</ref> | [[lamotrigine]] slow release<ref>https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lamictal_XR/pdf/LAMICTAL-XR-PI-MG.PDF</ref> | ||
risk increases conmmitant administration with valproate | risk increases conmmitant administration with valproate | ||
Revision as of 19:21, 15 April 2016
lamotrigine slow release[1] risk increases conmmitant administration with valproate
Stevens Johnson has been observed in 8 per 1000 cases
this presentation is indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older.